{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"19.0","value":"12.0"},{"groupId":"OG001","lowerLimit":"11.0","upperLimit":"15.0","value":"12.0"},{"groupId":"OG002","lowerLimit":"9.0","upperLimit":"16.0","value":"13.0"},{"groupId":"OG003","lowerLimit":"7.0","upperLimit":"13.0","value":"10.0"},{"groupId":"OG004","lowerLimit":"2.0","upperLimit":"19.0","value":"12.0"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"85"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"92"}],"units":"Transplants with PMN engraftment"}],"description":"The number of days from transplantation to successful engraftment as measured by PMN \\>=0.5\\*10\\^9 /L for 3 days or \\>=1.0\\*10\\^9 /L for 1 day.","dispersionType":"Full Range","groups":[{"description":"Participants with non-Hodgkin's lymphoma (NHL) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma"},{"description":"Participants with Hodgkin's disease (HD) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Hodgkin's Disease"},{"description":"Participants with multiple myeloma (MM) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG002","title":"Multiple Myeloma"},{"description":"Participants with 'other' cancers (desmoplastic small round cell tumor, acute myeloid leukemia, and testicular cancer) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG003","title":"Other Cancers"},{"id":"OG004","title":"All Patients"}],"paramType":"MEDIAN","populationDescription":"Participants who received a transplant and had a successful PMN engraftment. Seven participants (4 with HD, 2 with MM, and 1 with testicular cancer) received a second transplant. Two transplants (1 in a participant with NHL and 1 in a participant with MM) did not result in PMN engraftment and are therefore not included in the analysis.","reportingStatus":"POSTED","timeFrame":"approximately 2 months (1 month post transplant)","title":"Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment","type":"SECONDARY","typeUnitsAnalyzed":"Transplants with PMN engraftment","unitOfMeasure":"Days"}